61 research outputs found
ROS signaling by NADPH oxidase 5 modulates the proliferation and survival of prostate carcinoma cells
Immunohistochemical Analysis of Advanced Human Breast Carcinomas Reveals Downregulation of Protein Kinase Cα
Mechanism of drug-induced inhibition of keratinocyte proliferation: antagonism of calmodulin or inhibition of protein kinase C?
1-Dehydro-melengestrol acetate inhibitis the growth and protein kinase C activity of androgen-independent Dunning rat prostatic tumors
Kinase targets in CNS drug discovery
Originally thought to be nondruggable, kinases represent attractive drug targets for pharmaceutical companies and academia. To date, there are over 40 kinase inhibitors approved by the US FDA, with 32 of these being small molecules, in addition to the three mammalian target of rapamycin inhibitor macrolides (sirolimus, temsirolimus and everolimus). Despite the rapid development of kinase inhibitors for cancer, presently none of these agents are approved for CNS indications. This mini perspective highlights selected kinase targets for CNS disorders, of which brain-permeable small-molecule inhibitors are reported, with demonstrated preclinical proof-of-concept efficacy. This is followed by a brief discussion on the key challenges of blood-brain barrier penetration and selectivity profiles in developing kinase inhibitors for CNS disorders
Serrated neoplasias and de novo carcinomas in ulcerative colitis: A histological study in colectomy specimens
The selective inhibition of nuclear PKCζ restores the effectiveness of chemotherapeutic agents in chemoresistant cells
Comparative analysis of the effects of four mood stabilizers in SH-SY5Y cells and in primary neurons
- …